Kazakhstan One-Window Pilot 2026: Medical Device Registration in 100 Working Days

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

From April 6, 2026, Kazakhstan extended the one-window (одно окно) combined service pilot, applicable to legal relations arising between January 1, 2026 and December 31, 2026. Through the e-government portal, a single combined service merges expert review, registration and re-registration, registration dossier changes, manufacturer price registration and adjustment, and the formation of the Kazakhstan national medicines catalogue into one digital entry point. The total duration of the combined service is no more than 100 working days; the applicant must confirm within 30 working days whether it agrees to accept an inspection; the inspection itself lasts up to 90 working days. These four figures form the basic skeleton of Kazakhstan registration scheduling in 2026. For comparison, the conventional national procedure allows 110 working days for review where laboratory studies are required and 70 working days where they are not, so the pilot represents a genuine compression of the chain rather than a re-badging of old timelines. Because the service merges several previously separate administrative procedures, applicants also save the handover time between those procedures, which never appeared in any statutory timeline but always appeared in real project calendars.

2. Legal basis

InstrumentReference numberDateProvisions
Joint order of the Minister of Health and the Minister of Digital Development (extending the one-window combined service pilot)No. 30 / No. 140March 11, 2026 / March 12, 2026effective April 6, 2026; applies from January 1, 2026 to December 31, 2026
Order of the Minister of Health of Kazakhstan approving the Rules for National Registration, Re-registration and Changes to Registration Dossiers of Medicines and Medical DevicesNo. ҚР ДСМ-16February 9, 2021 (Ministry of Justice registration No. 22175)conventional national registration procedure and timelines
Order of the Minister of Health of Kazakhstan approving the Rules for the Expert Assessment (Expert Review) of the Safety, Quality and Efficacy of Medicines and Medical DevicesNo. ҚР ДСМ-10January 27, 2021organization of review and inspections
Tax Code of the Republic of KazakhstanCode No. 214-VIIIsigned July 18, 2025, effective January 1, 2026state fees (registration 11 МРП; re-registration 5 МРП)

3. Expert insights

Insight one: 100 working days is the combined-service figure, running in parallel with the conventional figures. Under Kazakhstan’s conventional national procedure, the review timeline is 110 working days where laboratory studies are required and 70 working days where they are not, and a manufacturing site inspection takes up to 90 working days, which is not counted within the review period. The one-window pilot bundles the entire chain into a single combined service with a compressed limit of 100 working days. The two sets of figures run in parallel, and which one actually applies depends on the filing channel and the type of dossier. Before committing to a schedule, confirm expressly which regime your submission falls under, because the difference is material for any launch date. A written confirmation of the applicable regime at the start of the project protects the schedule against later disagreement about which figures govern.

Insight two: the 100 working days exclude four categories of time, and the real cycle must be built by adding them back. Explicitly excluded from the total duration are: time for remedying the dossier, time for the applicant to submit supplementary materials, the organization and conduct of inspections, expert commission procedures, and the approval of final documents. When modeling a project plan, companies should treat the real cycle as 100 working days plus remedies plus inspection, rather than reading 100 as the delivery date. A project that builds its launch campaign around the bare figure will discover too late that a single remedy round can shift every downstream milestone.

Insight three: the pilot runs for one year, and its continuation next year is uncertain. The joint order expressly applies to legal relations arising between January 1, 2026 and December 31, 2026. For projects whose cycle crosses into 2027, it cannot be assumed that the pilot will continue automatically. The GRZAN recommendation is to spend the pilot’s timeline advantage on projects that can realistically complete within 2026, and to plan longer-cycle projects against the conventional procedure so that a change of regime does not invalidate the plan midway. Where a 2027 completion is plausible but not certain, draft the plan in two versions, one under the pilot and one under the conventional procedure.

Insight four: digital submission amplifies the value of dossier quality. A single digital entry point, integrated systems and transparent process status mean that the number of remedy rounds becomes the core variable determining the cycle. The pilot has removed much of the process friction that used to sit between the applicant and the authority, and nearly all of the remaining variance now lands on the quality of the dossier itself. In this environment, an extra week spent on internal dossier review before submission is the cheapest acceleration available. The same logic applies to translations, since poor translation quality is itself a recurring remedy trigger.

4. Practical recommendations

  1. Model the schedule as 100 working days plus remedies plus inspection; do not use the bare 100 working days as the delivery date.
  2. Confirm acceptance of the inspection within 30 working days of receiving the notification; delay here drags down the entire timeline.
  3. Reserve an inspection window of up to 90 working days and complete a self-audit of the manufacturing site in advance.
  4. For projects whose cycle may cross into 2027, confirm in advance whether the pilot will be extended.
  5. Concentrate resources on dossier quality to reduce remedy rounds, which is the most effective acceleration lever under the pilot.

5. Verification checklist

  • □ Applicability of the one-window combined service pilot confirmed (legal relations arising in 2026)
  • □ The schedule model includes remedy and inspection time beyond the 100 working days
  • □ The 30 working days deadline for inspection confirmation is in the project calendar with reminders set
  • □ An inspection window of up to 90 working days has been reserved
  • □ For projects crossing into 2027, the continuation status of the pilot has been confirmed
  • □ A dossier quality check was completed before submission and remedy risk has been minimized

GRZAN provides registration support in Kazakhstan for medical device manufacturers, importers and authorized representatives, covering combined-service filings, dossier preparation, inspection coordination and post-grant registration maintenance. For assistance with this topic, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail